WHO urges member states to enhance transparency in drug costsMay 29, 2019
The World Health Assembly, in a recent meeting. adopted resolution urging the WHO Member States to enhance transparency of markets for medicines, vaccines and other health products.
The member states are recommended to enhance public sharing of information on actual prices paid by governments and other buyers for health products, and improve transparency on pharmaceutical patents, clinical trial results and other determinants of pricing along the value chain from laboratory to patient.
The resolution aims at helping countries to make more informed decisions when purchasing health products, negotiate more affordable prices and ultimately expand access to health products for the populations.
The assembly has requested the WHO secretariat to support efforts towards transparency and monitor the impact of it on affordability and availability of health products, including the effect of differential pricing.
WHO reported that the progress on the issue will be assessed by the WHO Access Roadmap for Medicines, Vaccines and other health products, for the next five years.